Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion.
Latini R, Masson S, Jeremic G, Luvarà G, Fiordaliso F, Calvillo L, Bernasconi R, Torri M, Rondelli I, Razzetti R, Bongrani S. Latini R, et al. Among authors: torri m. J Cardiovasc Pharmacol. 1998 Apr;31(4):601-8. doi: 10.1097/00005344-199804000-00020. J Cardiovasc Pharmacol. 1998. PMID: 9554811
Effects of a DA2/alpha2 agonist and a beta1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion.
Masson S, Masseroli M, Fiordaliso F, Calvillo L, D'Aquila S, Bernasconi R, Garrido G, Torri M, Razzetti R, Bongrani S, Latini R. Masson S, et al. Among authors: torri m. J Cardiovasc Pharmacol. 1999 Sep;34(3):321-6. doi: 10.1097/00005344-199909000-00001. J Cardiovasc Pharmacol. 1999. PMID: 10470987
Within-patient variability of hormone and cytokine concentrations in heart failure.
Masson S, Latini R, Bevilacqua M, Vago T, Sessa F, Torri M, Anesini A, Salio M, Pasotti E, Agnello D, Santoro L, Catania A, Ghezzi P, Moccetti T, Maggioni AP. Masson S, et al. Among authors: torri m. Pharmacol Res. 1998 Mar;37(3):213-7. doi: 10.1006/phrs.1998.0288. Pharmacol Res. 1998. PMID: 9602470 Clinical Trial.
Structure-based design and synthesis of novel potent Na+,K+ -ATPase inhibitors derived from a 5alpha,14alpha-androstane scaffold as positive inotropic compounds.
De Munari S, Cerri A, Gobbini M, Almirante N, Banfi L, Carzana G, Ferrari P, Marazzi G, Micheletti R, Schiavone A, Sputore S, Torri M, Zappavigna MP, Melloni P. De Munari S, et al. Among authors: torri m. J Med Chem. 2003 Aug 14;46(17):3644-54. doi: 10.1021/jm030830y. J Med Chem. 2003. PMID: 12904068
Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold.
Gobbini M, Armaroli S, Banfi L, Benicchio A, Carzana G, Ferrari P, Giacalone G, Marazzi G, Moro B, Micheletti R, Sputore S, Torri M, Zappavigna MP, Cerri A. Gobbini M, et al. Among authors: torri m. Bioorg Med Chem. 2010 Jun 15;18(12):4275-99. doi: 10.1016/j.bmc.2010.04.095. Epub 2010 May 20. Bioorg Med Chem. 2010. PMID: 20494582
44 results